Volume 15, Issue 8 (November 2021)                   Qom Univ Med Sci J 2021, 15(8): 550-563 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rostami E, Heidari R, Shirzad ‪, Motevaseli E, Mazlumi M A. Comparison of the Effects of Native and Commercial Probiotic on Gluten Degradation. Qom Univ Med Sci J 2021; 15 (8) :550-563
URL: http://journal.muq.ac.ir/article-1-3050-en.html
Comparison of the Effects of Native and Commercial Probiotic on Gluten Degradation
Elham Rostami1 , Reza Heidari2 , ‪Mahdieh Shirzad3 , Elahe Motevaseli4 , Mohammad Ali Mazlumi * 5
1- Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
2- Research Center for Cancer Screening and Epidemiology, AJA University of Medical Sciences, Tehran, Iran.
3- Department of Microbial Biotechnology, School of Biology and Center of Excellence in Phylogeny of Living Organisms, University of Tehran, College of Science, Tehran, Iran.
4- Department of Molecular Medicine, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
5- Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran. , m-mazlomi@tums.ac.ir
Abstract:   (1420 Views)
Background and Objectives: The main treatment for celiac disease is a gluten-free diet. Gluten infection occurs in 55%-32% of these patients, which can cause symptoms in these patients. Many patients with celiac disease are dissatisfied with a gluten-free diet and are interested in a non-dietary alternative treatment.
Methods: In this study, probiotic samples of local dairy (milk, yogurt, and cheese) from Iran were collected in sterile conditions and after enzymatic extraction using a lysis buffer and a sonication method for enzyme activity of prolyl endopeptidase and aminopeptidase N were evaluated.
Results: The highest absorption rate for Z-Gly-Pro-4-nitroanilide substrate that performs the evaluation of prolyl endopeptidase enzyme, respectively, for strains C10-1 (L. pentosus), B6-1 (L. fermentum), C5-2 (L.paracasei), Y5 (L.paracasei) and C11-1 (L. pentosus) and in relation to Leu-p-NA which assesses aminopeptidase N The highest uptake was observed for strains K1 (L. helveticus), B8-2 (L. plantarum), Y5 (L.paracasei), P2-3 and P35 (L. plantarum), respectively. All of the above strains showed significantly different uptake than the negative control containing buffer and substrate (P<0.05). Finally, the 16s rRNA sequence of the isolated strains was registered in NCBI database.
Conclusion: The results of the present study showed that number of native Iranian probiotics have effective activity of prolyl endopeptidase and aminopeptidase N which can be used as a selective combination for gluten degradation and to help celiac patients.
Keywords: Probiotics, Glutens, Celiac disease, Prolyl oligopeptidases, Aminopeptidase N
Full-Text [PDF 5162 kb]   (486 Downloads)    
Type of Study: Original Article | Subject: تغذیه
Received: 2021/01/31 | Accepted: 2021/10/23 | Published: 2021/11/1
References
1. Caio G, Volta U, Sapone A, Leffler DA, De Giorgio R, Catassi C, et al. Celiac disease: A comprehensive current review. BMC Med. 2019; 17(1):142. [DOI:10.1186/s12916-019-1380-z] [PMID] [PMCID] [DOI:10.1186/s12916-019-1380-z]
2. Singh P, Arora A, Strand TA, Leffler DA, Catassi C, Green PH, et al. Global prevalence of Celiac disease: Systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018; 16(6):823-36.e2. [DOI:10.1016/j.cgh.2017.06.037] [PMID] [DOI:10.1016/j.cgh.2017.06.037]
3. Losowsky MS. A history of Coeliac disease. Dig Dis. 2008; 26(2):112-20. [DOI:10.1159/000116768] [PMID] [DOI:10.1159/000116768]
4. Chander AM, Yadav H, Jain S, Bhadada SK, Dhawan DK. Cross-talk between gluten, intestinal microbiota and intestinal mucosa in Celiac disease: Recent advances and basis of autoimmunity. Front Microbiol. 2018; 9:2597. [DOI:10.3389/fmicb.2018.02597] [PMID] [PMCID] [DOI:10.3389/fmicb.2018.02597]
5. Uhde M, Yu X, Bunin A, Brauner C, Lewis SK, Lebwohl B, et al. Phenotypic shift of small intestinal intra-epithelial type 1 innate lymphoid cells in Celiac disease is associated with enhanced cytotoxic potential. Clin Exp Immunol. 2020; 200(2):163-75. [DOI:10.1111/cei.13414] [PMID] [PMCID] [DOI:10.1111/cei.13414]
6. Fasano A. Clinical presentation of Celiac disease in the pediatric population. Gastroenterology. 2005; 128(4):S68-73. [DOI:10.1053/j.gastro.2005.02.015] [PMID] [DOI:10.1053/j.gastro.2005.02.015]
7. Coqueiro A, Bonvini A, Tirapegui J, Rogero M. Probiotics supplementation as an alternative method for Celiac disease treatment. Int J Probiotics Prebiotics. 2016; 12(1):23-32. https://www.researchgate.net/publication/318351358_Probiotics_supplementation_as_an_alternative_method_for_celiac_disease_treatment
8. Bascunan KA, Vespa MC, Araya M. Celiac disease: Understanding the gluten-free diet. Eur J Nutr. 2017; 56(2):449-59. [DOI:10.1007/s00394-016-1238-5] [PMID] [DOI:10.1007/s00394-016-1238-5]
9. de Sousa Moraes LF, Grzeskowiak LM, de Sales Teixeira TF, Gouveia Peluzio Mdo C. Intestinal microbiota and probiotics in Celiac disease. Clin Microbiol Rev. 2014; 27(3):482-9. [DOI:10.1128/CMR.00106-13] [PMID] [PMCID] [DOI:10.1128/CMR.00106-13]
10. Bozzi Cionci N, Baffoni L, Gaggìa F, Di Gioia DD. Therapeutic microbiology: The role of bifidobacterium breve as food supplement for the prevention/treatment of paediatric diseases. Nutrients. 2018; 10(11):1723. [DOI:10.3390/nu10111723] [PMID] [PMCID] [DOI:10.3390/nu10111723]
11. Vlasova AN, Kandasamy S, Chattha KS, Rajashekara G, Saif LJ. Comparison of probiotic lactobacilli and bifidobacteria effects, immune responses and rotavirus vaccines and infection in different host species. Vet Immunol Immunopathol. 2016; 172:72-84. [DOI:10.1016/j.vetimm.2016.01.003] [PMID] [PMCID] [DOI:10.1016/j.vetimm.2016.01.003]
12. Kailasapathy K. Microencapsulation of probiotic bacteria: Technology and potential applications. Curr Issues Intest Microbiol. 2002; 3(2):39-48. [PMID]
13. Chae CS, Kwon HK, Hwang JS, Kim JE, Im SH. Prophylactic effect of probiotics on the development of experimental autoimmune myasthenia gravis. PloS One. 2012; 7(12):e52119. [DOI:10.1371/journal.pone.0052119] [PMID] [PMCID] [DOI:10.1371/journal.pone.0052119]
14. Dickerson FB, Stallings C, Origoni A, Katsafanas E, Savage CL, Schweinfurth LA, et al. Effect of probiotic supplementation on Schizophrenia symptoms and association with gastrointestinal functioning: A randomized, placebo-controlled trial. Prim Care Companion CNS Disord. 2014; 16(1):PCC. [DOI:10.4088/PCC.13m01579] [PMID] [PMCID] [DOI:10.4088/PCC.13m01579]
15. Norouzbeigi S, Vahid-Dastjerdi L, Yekta R, Sohrabvandi S, Zendeboodi F, Mortazavian AM. Celiac therapy by administration of probiotics in food products: A review. Curr Opin Food Sci. 2020; 32:58-66. [DOI:10.1016/j.cofs.2020.01.005] [DOI:10.1016/j.cofs.2020.01.005]
16. Giorgi A, Cerrone R, Capobianco D, Filardo S, Mancini P, Zanni F, et al. A probiotic preparation hydrolyzes gliadin and protects intestinal cells from the toxicity of pro-inflammatory peptides. Nutrients. 2020; 12(2):495. [DOI:10.3390/nu12020495] [PMID] [PMCID] [DOI:10.3390/nu12020495]
17. Kelly CP, Bai JC, Liu E, Leffler DA. Advances in diagnosis and management of Celiac disease. Gastroenterology. 2015; 148(6):1175-86. [DOI:10.1053/j.gastro.2015.01.044] [PMID] [PMCID] [DOI:10.1053/j.gastro.2015.01.044]
18. Mohammadibakhsh R, Sohrabi R, Salemi M, Mirghaed MT, Behzadifar M. Celiac disease in Iran: A systematic review and meta-analysis. Electron Physician. 2017; 9(3):3883-95. [DOI:10.19082/3883] [PMID] [PMCID] [DOI:10.19082/3883]
19. Green PHR, Cellier C. Celiac disease. N Engl J Med. 2007; 357(17):1731-43. [DOI:10.1056/NEJMra071600] [PMID] [DOI:10.1056/NEJMra071600]
20. Shirzad M, Hamedi J, Motevaseli E, Modarressi MH. Anti-elastase and anti-collagenase potential of Lactobacilli exopolysaccharides on human fibroblast. Artif Cells Nanomed Biotechnol. 2018; 46(sup1):1051-61. [DOI:10.1080/21691401.2018.1443274] [PMID] [DOI:10.1080/21691401.2018.1443274]
21. Zhang Z, Lv J, Pan L, Zhang Y. Roles and applications of probiotic Lactobacillus strains. Appl Microbiol Biotechnol. 2018; 102(19):8135-43. [DOI:10.1007/s00253-018-9217-9] [PMID] [DOI:10.1007/s00253-018-9217-9]
22. Francavilla R, De Angelis M, Rizzello CG, Cavallo N, Dal Bello F, Gobbetti M. Selected probiotic lactobacilli have the capacity to hydrolyze gluten peptides during simulated gastrointestinal digestion. Appl Environ Microbiol. 2017; 83(14):e00376-17. [DOI:10.1128/AEM.00376-17] [PMID] [PMCID] [DOI:10.1128/AEM.00376-17]
23. Duar RM, Clark KJ, Patil PB, Hernández C, Brüning S, Burkey TE, et al. Identification and characterization of intestinal lactobacilli strains capable of degrading immunotoxic peptides present in gluten. J Appl Microbiol. 2015; 118(2):515-27. [DOI:10.1111/jam.12687] [PMID] [DOI:10.1111/jam.12687]
24. Caminero A, Herrán AR, Nistal E, Pérez-Andrés J, Vaquero L, Vivas S, et al. Diversity of the cultivable human gut microbiome involved in gluten metabolism: Isolation of microorganisms with potential interest for coeliac disease. FEMS Microbiol Ecol. 2014; 88(2):309-19. [DOI:10.1111/1574-6941.12295] [PMID] [DOI:10.1111/1574-6941.12295]
25. Marasco G, Di Biase AR, Schiumerini R, Eusebi LH, Iughetti L, Ravaioli F, et al. Gut microbiota and Celiac disease. Dig Dis Sci. 2016; 61(6):1461-72. [DOI:10.1007/s10620-015-4020-2] [PMID] [DOI:10.1007/s10620-015-4020-2]
26. Bakshi A, Stephen S, Borum ML, Doman DB. Emerging therapeutic options for Celiac disease: Potential alternatives to a gluten-free diet. Gastroenterol Hepatol (N Y). 2012; 8(9):582-8. [PMID] [PMCID]
27. Håkansson Å, Andrén Aronsson C, Brundin C, Oscarsson E, Molin G, Agardh D. Effects of Lactobacillus Plantarum and Lactobacillus Paracasei on the peripheral immune response in children with Celiac disease autoimmunity: A randomized, double-blind, placebo-controlled clinical trial. Nutrients. 2019; 11(8):1925. [DOI:10.3390/nu11081925] [PMID] [PMCID] [DOI:10.3390/nu11081925]
28. Francavilla R, De Angelis M, Rizzello CG, Cavallo N, Dal Bello F, Gobbetti M. Selected probiotic lactobacilli have the capacity to hydrolyze gluten peptides during simulated gastrointestinal digestion. Appl Environ Microbiol. 2017; 83(14):e00376-17. [DOI:10.1128/AEM.00376-17] [PMID] [PMCID] [DOI:10.1128/AEM.00376-17]
29. Riaz Rajoka MS, Zhao H, Lu Y, Lian Z, Li N, Hussain N, et al. Anticancer potential against cervix cancer (HeLa) cell line of probiotic Lactobacillus Casei and Lactobacillus Paracasei strains isolated from human breast milk. Food Funct. 2018; 9(5):2705-15. [DOI:10.1039/C8FO00547H] [PMID] [DOI:10.1039/C8FO00547H]
30. Kim WK, Jang YJ, Seo B, Han DH, Park S, Ko GP. Administration of Lactobacillus paracasei strains improves immunomodulation and changes the composition of gut microbiota leading to improvement of colitis in mice. J Funct Foods. 2019; 52:565-75. [DOI:10.1016/j.jff.2018.11.035] [DOI:10.1016/j.jff.2018.11.035]
31. Yao F, Jia R, Huang H, Yu Y, Mei L, Bai L, et al. Effect of Lactobacillus paracasei N1115 and fructooligosaccharides in nonalcoholic fatty liver disease. Arch Med Sci. 2019; 15(5):1336-44. [DOI:10.5114/aoms.2019.86611] [PMID] [PMCID] [DOI:10.5114/aoms.2019.86611]
32. Barone R, Rappa F, Macaluso F, Caruso Bavisotto C, Sangiorgi C, Di Paola G, et al. Alcoholic liver disease: A mouse model reveals protection by Lactobacillus
Add your comments about this article : Your username or Email:
CAPTCHA
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2025 CC BY-NC 4.0 | Qom University of Medical Sciences Journal

Designed & Developed by : Yektaweb